Their non-stem cell drugs at the very least support a market cap of 200-300+ mil imho. Add in the cash and you're getting the stem cell patents, potential cures for next to nothing. Geron's biggest problem is getting it's story out imho as evidenced by the recent rise of STEM, ASTM, and VIAC. Bush doesn't help matters, but again I would argue that it's mostly perception. Bush is not trying to kill embryonic stem cell research or cures.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.